Skip to content

Study on the Expression Levels of Novel Thrombus Markers in Different Pathogenesis Types of Blood Stasis Syndrome in Diabetes

Study on the Expression Levels of Novel Thrombus Markers in Different Pathogenesis Types of Blood Stasis Syndrome in Diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092453
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-11-18
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

consumptive thirst

Interventions

Qi stagnation blood stasis group:none
Phlegm dampness blood stasis group:none
Blood stasis stagnation group:none
Control group:none

Sponsors

Eye Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 50-80 years; 2.The patient meets the Western medical diagnostic criteria for type 2 diabetes; 3.During the patient's hospitalization, T2DR has been confirmed and should meet the staging and TCM syndrome diagnosis criteria of T2DR, and the medical records must be complete. 4. Willing to accept the research plan and agree to undergo relevant examinations; 5. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with acute complications such as diabetes ketone, diabetic hypertension and coma; 2. Those who have recently trauma, surgery and other stresses; 3. Those with acute and chronic infections, such as respiratory tract infections, urinary infections, etc.; 4. With hepatitis, cirrhosis of liver, liver cancer, pneumonia, COPD and lung cancer and other liver and lung diseases; 5. With serious renal insufficiency, cardio-cerebrovascular disorders or peripheral disorders, such as cardiac insufficiency, coronary artery disease, hypertensive disease, cerebral infarction, cerebral hemorrhage; 6. Merge other endocrine metabolic diseases, such as thyroid, pituitary and other diseases; 7. Severe macular degeneration, cataract, underground arteriosclerosis, bleeding, uveitis and other diseases; 8. Patients with long -term use of glucocorticoids or patients with large doses of hormones have been used for a long time; 9. People with gestational diabetes mellitus, type 1 diabetes mellitus and other special types of diabetes mellitus.

Design outcomes

Primary

MeasureTime frame
Glu;HbA1c;PIC;TAT;TM;tPAI?C;

Secondary

MeasureTime frame
INS;TC;TG;HDL-C;LDL-C;Cys C;HCY;UA;UACR;U-TP;

Countries

China

Contacts

Public ContactXiaoyue Wang

Eye Hospital China Academy of Chinese Medical Sciences

1328422572@qq.com+86 185 1934 2897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026